Biotech · Public company · Cambridge, MA, US

Agios Pharmaceuticals, Inc.

Ticker AGIO · SEC CIK 0001439222

Track this companyFree. Adds Agios Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials2515 recruiting or active

Pipeline programs17From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline17

MitapivatPhase 3 · Pediatric Pyruvate Kinase DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
MitapivatPhase 3 · Transfusion-dependent Alpha-ThalassemiaClinicalTrials.gov · fetched Nov 12, 2026
MitapivatPhase 3 · Sickle Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026
MitapivatPhase 3 · Pyruvate Kinase DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
MitapivatPhase 3 · Non-Transfusion-dependent Alpha-ThalassemiaClinicalTrials.gov · fetched Nov 12, 2026
AG-348Phase 2 · Pyruvate Kinase DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
AG-348Phase 2 · ThalassemiaClinicalTrials.gov · fetched Nov 12, 2026
TebapivatPhase 2 · Sickle Cell DiseaseClinicalTrials.gov · fetched Nov 12, 2026
TebapivatPhase 2 · Myelodysplastic SyndromesClinicalTrials.gov · fetched Nov 12, 2026
[13C2,15N3]-tebapivatPhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
[14C]-tebapivatPhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
AG-181Phase 1 · PhenylketonuriaClinicalTrials.gov · fetched Nov 12, 2026
AG-181Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
AG-236Phase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
AG-946Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
MidazolamPhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026
MitapivatPhase 1 · Healthy ParticipantsClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials25

A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)PHASE3 · RECRUITING · started Sep 24, 2026ClinicalTrials.gov NCT07506863 · fetched Nov 12, 2026
A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent ThalassemiaPHASE3 · RECRUITING · started Sep 1, 2026ClinicalTrials.gov NCT07517133 · fetched Nov 12, 2026
A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)PHASE3 · RECRUITING · started Jul 21, 2026ClinicalTrials.gov NCT07656415 · fetched Nov 12, 2026
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With PhenylketonuriaPHASE1 · RECRUITING · started Apr 17, 2026ClinicalTrials.gov NCT07241234 · fetched Nov 12, 2026
A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy ParticipantsPHASE1 · ACTIVE_NOT_RECRUITING · started Jul 7, 2025ClinicalTrials.gov NCT07075640 · fetched Nov 12, 2026
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)PHASE2 · ACTIVE_NOT_RECRUITING · started May 1, 2025ClinicalTrials.gov NCT06924970 · fetched Nov 12, 2026
A Study to Determine How Tebapivat is Absorbed, Broken Down, and Removed From the Body and the Extent to Which Tebapivat is Made Available in the Body in Healthy ParticipantsPHASE1 · COMPLETED · started Dec 20, 2024ClinicalTrials.gov NCT06745271 · fetched Nov 12, 2026
Study of How Mitapivat Affects Midazolam Blood Levels in Healthy ParticipantsPHASE1 · COMPLETED · started Oct 17, 2024ClinicalTrials.gov NCT06648824 · fetched Nov 12, 2026
Single and Multiple Ascending Dose Study and Food Effect Study for AG181PHASE1 · COMPLETED · started Feb 20, 2024ClinicalTrials.gov NCT06286033 · fetched Nov 12, 2026
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)PHASE2 · ACTIVE_NOT_RECRUITING · started Nov 7, 2022ClinicalTrials.gov NCT05490446 · fetched Nov 12, 2026
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Regularly Transfused, Followed by a 5-Year Extension PeriodPHASE3 · ACTIVE_NOT_RECRUITING · started Jun 8, 2022ClinicalTrials.gov NCT05144256 · fetched Nov 12, 2026
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension PeriodPHASE3 · ACTIVE_NOT_RECRUITING · started Jun 6, 2022ClinicalTrials.gov NCT05175105 · fetched Nov 12, 2026
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)PHASE2_PHASE3 · ACTIVE_NOT_RECRUITING · started Feb 11, 2022ClinicalTrials.gov NCT05031780 · fetched Nov 12, 2026
Acquired Pyruvate Kinase Deficiency In Clonal Myeloid NeoplasmsCOMPLETED · started Feb 1, 2022ClinicalTrials.gov NCT04902833 · fetched Nov 12, 2026
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)PHASE3 · ACTIVE_NOT_RECRUITING · started Dec 20, 2021ClinicalTrials.gov NCT04770753 · fetched Nov 12, 2026
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)PHASE3 · ACTIVE_NOT_RECRUITING · started Nov 30, 2021ClinicalTrials.gov NCT04770779 · fetched Nov 12, 2026
Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant TumorsPHASE2 · COMPLETED · started Sep 20, 2021ClinicalTrials.gov NCT04056910 · fetched Nov 12, 2026
A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-946 in Healthy Volunteers and in Participants With Sickle Cell DiseasePHASE1 · COMPLETED · started Jul 10, 2020ClinicalTrials.gov NCT04536792 · fetched Nov 12, 2026
AG-120 in People With IDH1 Mutant ChondrosarcomaPHASE2 · ACTIVE_NOT_RECRUITING · started Mar 4, 2020ClinicalTrials.gov NCT04278781 · fetched Nov 12, 2026
Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007PHASE3 · COMPLETED · started Mar 21, 2019ClinicalTrials.gov NCT03853798 · fetched Nov 12, 2026
A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent ThalassemiaPHASE2 · ACTIVE_NOT_RECRUITING · started Mar 20, 2019ClinicalTrials.gov NCT03692052 · fetched Nov 12, 2026
IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell TransplantationPHASE1 · COMPLETED · started Jan 16, 2019ClinicalTrials.gov NCT03564821 · fetched Nov 12, 2026
Pyruvate Kinase Deficiency Global Longitudinal RegistryACTIVE_NOT_RECRUITING · started Apr 23, 2018ClinicalTrials.gov NCT03481738 · fetched Nov 12, 2026
A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) DeficiencyPHASE2 · COMPLETED · started Jun 26, 2015ClinicalTrials.gov NCT02476916 · fetched Nov 12, 2026
Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) MutationPHASE1_PHASE2 · COMPLETED · started Aug 27, 2013ClinicalTrials.gov NCT01915498 · fetched Nov 12, 2026

SEC filings12

10-Q · 10-QSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed Jul 30, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jul 30, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jun 18, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed Apr 29, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Apr 29, 2026 · fetched Nov 12, 2026
10-K · 10-KSEC EDGAR · filed Feb 12, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Feb 12, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jan 12, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed Oct 30, 2025 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Oct 30, 2025 · fetched Nov 12, 2026